An invasive species of shrimp, commonly known as the ‘killer shrimp’, has been found at Grafham Water reservoir in Cambridgeshire – the first time the shrimp has been found in the UK. 10 September 2010
The UK launch of Sativex®, GW Pharmaceuticals’ oromucosal spray for the treatment of spasticity caused by multiple sclerosis, has been announced. 21 June 2010
Latest NICE cost–benefit guidance includes Sandoz’s Omnitrope® as one of seven recommended somatropin products to treat growth failure in children. 11 June 2010
Stakeholders celebrate ten years of success of the EU regulation on orphan medicines at the European Parliament. 04 June 2010
Amgen announced recently that Prolia (denosumab), a new type of osteoporosis treatment for post-menopausal women, has been granted marketing authorization in the UK. 03 June 2010
The convergence of active lifestyles, aging joints and a more enlightened approach by practitioners to treating pain is contributing to an attractive demand picture for pain management drug products. 12 March 2010
The Gastrointestinal Drugs Advisory Committee of the FDA has recommended the approval of XIFAXAN® (rifaximin) tablets (550 mg) for the maintenance of remission of hepatic encephalopathy. 24 February 2010
Silence Therapeutics announced recently that the United States Patent and Trademark Office has issued them a notice of allowance on a patent application covering a novel cancer target. 10 February 2010
Xiaflex has recently been approved to treat progressive hand disease Dupuytren's contracture, which can affect a person’s ability to straighten and use their fingers. 05 February 2010
Novo Nordisk has announced that the FDA has granted marketing authorization for Victoza® for the treatment of type 2 diabetes in adults. 02 February 2010
A drug safety warning from the MHRA on the dangers of switching immunosuppressants calls into question the safety of the Department of Health’s proposal for Automatic Generic Substitution. 01 February 2010
Astex Therapeutics announced recently that it has been granted orphan drug designation by the FDA for AT9283, its combinatorial oncogenic kinase inhibitor, for the treatment of patients with acute myeloid leukaemia. 24 November 2009
The Food and Drug Administration has approved the approval of Qutenza (capsaicin) 8% patch, a medicated skin patch that relieves the pain of post-herpetic neuralgia, a serious complication that can occur after a bout with shingles. 18 November 2009
Germany's Paul-Ehrlich-Institute approves clinical trial in rheumatoid arthritis patients. 09 November 2009
TikoMed AB announced recently that IBsolvMIR® has been granted orphan drug designation for the prevention of graft rejection during pancreatic islet transplantation by the Committee for Orphan Medicinal Products of the EMEA. 04 November 2009
The European Medicines Agency has been formally notified by AstraZeneca of its decision to withdraw its application for a centralized marketing authorization for the medicine Zactima (vandetinib) in 100 mg film-coated tablets. 02 November 2009
The new biological medicine Ilaris® (canakinumab) has been approved in the EU to treat adults and children as young as four years old with CAPS, a rare life-long auto-inflammatory disease. 30 October 2009
The U.S. Food and Drug Administration has approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukaemia, a slowly progressing cancer of the blood and bone marrow. 29 October 2009
The European Federation of Pharmaceutical Industries and Associations, the ‘voice of the research-based pharmaceutical industry in Europe’, today unveiled its pilot project to verify medicines and help reduce the risk of counterfeit medicines being dispensed to patients. 21 October 2009
Orphan drug designation ensures market exclusivity for seven to ten years after market approval. 16 September 2009
At least a quarter of people with heart disease don’t take vital medicines that have been prescribed to them to prevent heart attacks and strokes. 11 September 2009
The National Institute for Health and Clinical Excellence (NICE) recently issued guidance on the use of bevacizumab, sorafenib and temsirolimus for the treatment of renal cell carcinoma and the use of sorafenib and sunitinib for second-line treatment options for people with renal cell carcinoma. 02 September 2009
The National Institute for Health and Clinical Excellence (NICE) recently published final guidance on the use of cetuximab for the first-line treatment of metastatic colorectal cancer. 02 September 2009
Cleveland BioLabs, Inc. announced recently that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/421,918, titled ‘Modulating Apoptosis’. Allowed claims cover the method of protecting a mammal from radiation using flagellin or its derivatives, including Protectan CBLB502. 26 August 2009
The FDA is notifying the public about new safety information concerning products marketed for body building and increasing muscle mass. The FDA has sent a warning letter to a manufacturer of body building supplements that claim to contain steroid-like ingredients but in fact contain synthetic steroids. 29 July 2009
Email Address
Password
Forgotten login?